Novavax Inc (NVAX)

$7.84 +0.21 (2.75%)
Market Cap 1.24B
Revenue (ttm) 682.16M
Net Income (ttm) -187.50M
EPS (ttm) N/A
PE Ratio 3.83
Forward PE 3.27
Profit Margin -27.49%
Debt to Equity Ratio 0.00
Volume 8,465,600
Avg Vol 6,506,056
Day's Range N/A - N/A
Shares Out 162.42M
Stochastic %K 9%
Beta 2.50
Analysts Sell
Price Target $12.86

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 268 2000
Address:
700 Quince Orchard Road, Gaithersburg, United States
AJavier
AJavier Aug. 23 at 8:17 AM
$NVAX
0 · Reply
marti837
marti837 Aug. 23 at 7:35 AM
$NVAX It's almost impossible to predict. It depends on the spread of covid, partnership news, the spread of new viruses, etc. The weather affects it more than the financial situation.
0 · Reply
Chelsea100
Chelsea100 Aug. 23 at 6:56 AM
$NVAX my AI: Yes, absolutely. If Novavax lands a co-dev or licensing deal for its CIC product (Covid + Flu combo), we’re not talking peanuts – this is hundreds of millions to multi-billion potential. Why? • Market size: Global flu vax market is already $7–8B/yr, Covid vax peaked >$30B. A combo shot is the holy grail – one dose per season. • Upfront + milestones: Typically $100–300M upfront + >$1B in dev/reg milestones. • Royalties: 10–20% on sales in licensed regions. • Co-promotion: NVAX could keep rights in the US or select markets. 👉 If Sanofi, GSK or another big player steps in, it would be the largest deal in NVAX history – a true gamechanger for investors.
0 · Reply
Chelsea100
Chelsea100 Aug. 23 at 6:52 AM
$NVAX fuck, you re right. analyzed this with AI. Its ausual request from big BP ⸻ Novavax – CIC Partnership Setup? • Recent convertible restructuring: $225M 2031 notes, old 2027 debt almost wiped → balance sheet stabilized. • Classic precondition for a partnership: big pharma won’t sign unless the smaller partner looks financially secure. • Supply chain: Praha + Serum Institute = scalable, ready. • CIC program: clinical stage, regulatory clarity still pending → the next key trigger. • Mgmt tone shifting: “strengthening flexibility” → “ongoing strategic discussions.” • Odds: partnership probability ~55–60% now, jumps once CIC data/reg milestones hit. 👉 The debt restructuring wasn’t random – it likely clears the path for a CIC co-dev / co-promote deal (think Sanofi/GSK).
1 · Reply
abnormallyfatsack
abnormallyfatsack Aug. 23 at 5:51 AM
$NVAX Idk about you but I’m ready for some news that will electrify this to $90/share. Seems like it is ready to EXPLODE!! Just need a lil news from management. Or the government.
2 · Reply
Bodu
Bodu Aug. 23 at 5:50 AM
$NVAX Why refinance now for no reason? Why not wait for lower interest just announced by Powell? You can be sure there is a good reason. I have participated in a due diligence of few small suppliers before my (large company) partnered with them for the delivery of a key component we needed. Financial robustness of the small supplier was always the key question. Having a short term large debt would kill the partnership because of financial instability. Even if the small supplier had a very good product. I see much similarity to the coming Novavax CIC partnerships (CIC / matrix m …) Why the hurry to refinance now? Why not wait for the expected lower interest rate ? My true estimate is that they were forced to do it by the big pharma as a precondition to a large partnership. Just like Sanofi forced novavax to refinance the debt to GAVI before signing the partnership. This “ out of the blue “ refinancing that makes no sense is a true sign that something is cooking.
3 · Reply
e0fknu2k
e0fknu2k Aug. 23 at 4:18 AM
$NVAX Fort Henry in Kingston, Ontario, Canada! I wanted a green day on my birthday and that was too much to ask. We went on a sunset cruise today :-) Have a good weekend everyone...
0 · Reply
Orange_Shark
Orange_Shark Aug. 23 at 4:01 AM
$NVAX Back in. Grabbing 100 Jan 2027 20c on open. Sorry for ghosting guys, Seeing my my profits disappear due to crappy timing, I needed a few days-- plus moving and other things-- I'm back in and plan to hold calls until we break $25 from news.
0 · Reply
Stevewill66
Stevewill66 Aug. 23 at 3:13 AM
$NVAX good to see it move with market. Maybe the 6.99 Friday dudes are losing a bit of control maybe 🤔
0 · Reply
Ochayethenoo
Ochayethenoo Aug. 23 at 1:47 AM
$NVAX ... is this stonk a buy?
1 · Reply
Latest News on NVAX
Novavax Announces Convertible Debt Refinancing

Aug 21, 2025, 7:43 AM EDT - 1 day ago

Novavax Announces Convertible Debt Refinancing

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 3:56 PM EDT - 16 days ago

Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript

Novavax beats quarterly revenue estimates on milestone payment

Aug 6, 2025, 8:08 AM EDT - 16 days ago

Novavax beats quarterly revenue estimates on milestone payment

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 6, 2025, 8:00 AM EDT - 16 days ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 8:00 AM EDT - 23 days ago

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Jul 24, 2025, 11:02 AM EDT - 4 weeks ago

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Jul 24, 2025, 8:00 AM EDT - 4 weeks ago

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 8:59 PM EDT - 2 months ago

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Jun 11, 2025, 7:11 AM EDT - 2 months ago

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Jun 11, 2025, 7:00 AM EDT - 2 months ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Vaccine actions and policy positions under US Health Secretary Kennedy

Jun 10, 2025, 10:45 AM EDT - 2 months ago

Vaccine actions and policy positions under US Health Secretary Kennedy

BNTX MRNA PFE

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Jun 10, 2025, 9:30 AM EDT - 2 months ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

BNTX MRNA PFE

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Jun 10, 2025, 8:18 AM EDT - 2 months ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

BNTX MRNA PFE SNY

Novavax to Participate in Upcoming Investor Conferences

May 29, 2025, 8:00 AM EDT - 3 months ago

Novavax to Participate in Upcoming Investor Conferences

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

May 21, 2025, 8:15 AM EDT - 3 months ago

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

May 20, 2025, 4:34 PM EDT - 3 months ago

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

May 19, 2025, 12:15 PM EDT - 3 months ago

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

AZO TSLA

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

May 19, 2025, 9:27 AM EDT - 3 months ago

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

May 19, 2025, 7:16 AM EDT - 3 months ago

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 19, 2025, 7:00 AM EDT - 3 months ago

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

FDA approves Novavax COVID vaccine with new conditions

May 17, 2025, 10:26 PM EDT - 3 months ago

FDA approves Novavax COVID vaccine with new conditions

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

May 14, 2025, 10:46 PM EDT - 3 months ago

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

May 12, 2025, 12:45 PM EDT - 3 months ago

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

May 8, 2025, 1:31 PM EDT - 3 months ago

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:48 AM EDT - 3 months ago

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%

May 8, 2025, 11:12 AM EDT - 3 months ago

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%

Novavax swings to profit on lower expenses related to COVID shots

May 8, 2025, 8:06 AM EDT - 3 months ago

Novavax swings to profit on lower expenses related to COVID shots

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

May 8, 2025, 8:00 AM EDT - 3 months ago

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 3 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA PFE GSK IBB SRPT XBI

Novavax to Participate in BofA Securities 2025 Health Care Conference

May 7, 2025, 8:00 AM EDT - 3 months ago

Novavax to Participate in BofA Securities 2025 Health Care Conference

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

May 5, 2025, 8:00 AM EDT - 3 months ago

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025, 8:00 AM EDT - 4 months ago

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Novavax Appoints Charles Newton to Board of Directors

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Novavax Appoints Charles Newton to Board of Directors

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

Apr 25, 2025, 3:35 PM EDT - 4 months ago

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

Apr 25, 2025, 3:20 PM EDT - 4 months ago

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back

Apr 24, 2025, 6:04 AM EDT - 4 months ago

Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Apr 23, 2025, 5:00 PM EDT - 4 months ago

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

FDA asks Novavax for commitment on post-approval studies for COVID vaccine

Apr 23, 2025, 8:26 AM EDT - 4 months ago

FDA asks Novavax for commitment on post-approval studies for COVID vaccine

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Apr 15, 2025, 7:00 AM EDT - 4 months ago

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

Apr 10, 2025, 3:02 PM EDT - 4 months ago

Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.

Apr 2, 2025, 1:20 PM EDT - 5 months ago

The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.

FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports

Apr 2, 2025, 12:29 PM EDT - 5 months ago

FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports

Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 5 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA PFE PCVX PTCT XBI

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Mar 31, 2025, 2:41 PM EDT - 5 months ago

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

BNTX MRNA PFE

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 5 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX SLDB SRPT TSHA XBI

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

Mar 31, 2025, 10:13 AM EDT - 5 months ago

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

BNTX MRNA PFE

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

Mar 31, 2025, 7:25 AM EDT - 5 months ago

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

BNTX MRNA PFE

Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)

Mar 11, 2025, 7:48 PM EDT - 5 months ago

Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)

Novavax Announces Changes to Board of Directors

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Novavax Announces Changes to Board of Directors

Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)

Mar 4, 2025, 1:34 PM EST - 6 months ago

Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)

AJavier
AJavier Aug. 23 at 8:17 AM
$NVAX
0 · Reply
marti837
marti837 Aug. 23 at 7:35 AM
$NVAX It's almost impossible to predict. It depends on the spread of covid, partnership news, the spread of new viruses, etc. The weather affects it more than the financial situation.
0 · Reply
Chelsea100
Chelsea100 Aug. 23 at 6:56 AM
$NVAX my AI: Yes, absolutely. If Novavax lands a co-dev or licensing deal for its CIC product (Covid + Flu combo), we’re not talking peanuts – this is hundreds of millions to multi-billion potential. Why? • Market size: Global flu vax market is already $7–8B/yr, Covid vax peaked >$30B. A combo shot is the holy grail – one dose per season. • Upfront + milestones: Typically $100–300M upfront + >$1B in dev/reg milestones. • Royalties: 10–20% on sales in licensed regions. • Co-promotion: NVAX could keep rights in the US or select markets. 👉 If Sanofi, GSK or another big player steps in, it would be the largest deal in NVAX history – a true gamechanger for investors.
0 · Reply
Chelsea100
Chelsea100 Aug. 23 at 6:52 AM
$NVAX fuck, you re right. analyzed this with AI. Its ausual request from big BP ⸻ Novavax – CIC Partnership Setup? • Recent convertible restructuring: $225M 2031 notes, old 2027 debt almost wiped → balance sheet stabilized. • Classic precondition for a partnership: big pharma won’t sign unless the smaller partner looks financially secure. • Supply chain: Praha + Serum Institute = scalable, ready. • CIC program: clinical stage, regulatory clarity still pending → the next key trigger. • Mgmt tone shifting: “strengthening flexibility” → “ongoing strategic discussions.” • Odds: partnership probability ~55–60% now, jumps once CIC data/reg milestones hit. 👉 The debt restructuring wasn’t random – it likely clears the path for a CIC co-dev / co-promote deal (think Sanofi/GSK).
1 · Reply
abnormallyfatsack
abnormallyfatsack Aug. 23 at 5:51 AM
$NVAX Idk about you but I’m ready for some news that will electrify this to $90/share. Seems like it is ready to EXPLODE!! Just need a lil news from management. Or the government.
2 · Reply
Bodu
Bodu Aug. 23 at 5:50 AM
$NVAX Why refinance now for no reason? Why not wait for lower interest just announced by Powell? You can be sure there is a good reason. I have participated in a due diligence of few small suppliers before my (large company) partnered with them for the delivery of a key component we needed. Financial robustness of the small supplier was always the key question. Having a short term large debt would kill the partnership because of financial instability. Even if the small supplier had a very good product. I see much similarity to the coming Novavax CIC partnerships (CIC / matrix m …) Why the hurry to refinance now? Why not wait for the expected lower interest rate ? My true estimate is that they were forced to do it by the big pharma as a precondition to a large partnership. Just like Sanofi forced novavax to refinance the debt to GAVI before signing the partnership. This “ out of the blue “ refinancing that makes no sense is a true sign that something is cooking.
3 · Reply
e0fknu2k
e0fknu2k Aug. 23 at 4:18 AM
$NVAX Fort Henry in Kingston, Ontario, Canada! I wanted a green day on my birthday and that was too much to ask. We went on a sunset cruise today :-) Have a good weekend everyone...
0 · Reply
Orange_Shark
Orange_Shark Aug. 23 at 4:01 AM
$NVAX Back in. Grabbing 100 Jan 2027 20c on open. Sorry for ghosting guys, Seeing my my profits disappear due to crappy timing, I needed a few days-- plus moving and other things-- I'm back in and plan to hold calls until we break $25 from news.
0 · Reply
Stevewill66
Stevewill66 Aug. 23 at 3:13 AM
$NVAX good to see it move with market. Maybe the 6.99 Friday dudes are losing a bit of control maybe 🤔
0 · Reply
Ochayethenoo
Ochayethenoo Aug. 23 at 1:47 AM
$NVAX ... is this stonk a buy?
1 · Reply
DallasNV
DallasNV Aug. 23 at 12:16 AM
$NVAX I'd like them to say: we've secured a great new financing package with better terms and a new term. With the 50 million, we'll of course pay off some of the damn convertible bonds again, and we've also decided to pay off debt by 50 million annually during good years, so that in the best case scenario, we can be debt-free by 2028/29. Saying something like that would cost nothing but would bring about enormous appreciation.
1 · Reply
mstan
mstan Aug. 23 at 12:12 AM
$NVAX bounce above 200MA . Patiently waiting for smoke and mirrors to clear out. And then to the 🌙Have a great weekend bulls and don't get emotional about SP MM is playing games with you.
0 · Reply
pissed_of_retards
pissed_of_retards Aug. 22 at 11:45 PM
$NVAX if $INTC with net profit -$20B is valued 2xPS then this should be at least $16
1 · Reply
deerix
deerix Aug. 22 at 11:10 PM
$OPEN $NVAX $CNC 8x💯 AND COUNTING ✅️✅️⬇️ Follow the number one transparent trader ➡️ VIEW PINNED IN PROFILE -posted this one many times 👀
1 · Reply
DerFrank
DerFrank Aug. 22 at 10:27 PM
$NVAX Most likely the debt restructure too a month or two, and due to reporting requirements they just had to file and couldn't change timing. Likely they send out notices to existing bondholders with a deadline to reply. Looks like most too the deal, and some didn't. Novavax should have given more color on the background process in their PR to soften the blow.
1 · Reply
BearBull777
BearBull777 Aug. 22 at 9:36 PM
$NVAX seems that $7.70/ $7.80 is now support. Praying for a good week next week
2 · Reply
ejaXstoXX
ejaXstoXX Aug. 22 at 9:20 PM
$NVAX Current Number: Around 830 million people aged 65+. Current Percentage: Approximately 10.3% of the global population. Rapid Growth: The number of older adults is expected to nearly double in less than 20 years reaching an estimated 1.6 billion.
0 · Reply
ejaXstoXX
ejaXstoXX Aug. 22 at 9:14 PM
$NVAX Sanofi understands the blockbuster potential of Nuvaxovid. An aging global population, with seniors having higher vaccination rates, fuels demand. 55% of global seniors >65y receive HD flu vaccines annually. 39.6% of global seniors >65y receive covid vaccines annually.
0 · Reply
DarvasBoxing
DarvasBoxing Aug. 22 at 8:59 PM
$NVAX have a great weekend kings and longs for now.
0 · Reply
averageshmo
averageshmo Aug. 22 at 8:53 PM
$NVAX I bought Jan 2027 leaps today. I have no idea what I’m doing when it comes to options but this is a lotto ticket I’m willing to lose money on.
1 · Reply
BTC321
BTC321 Aug. 22 at 8:31 PM
$NVAX bye bye mRNA! https://x.com/childrenshd/status/1958950362880397682?s=46&t=X6qO3UejysWvD0UxMTsJrA
4 · Reply
Zeger
Zeger Aug. 22 at 8:09 PM
$NVAX Every time I make a plan, buy nio, xpev, rivian low and plan to hold…and yes, I made some nice profits in the past few weeks…but then, right before EVs start to moon I jump over to novavax coz of FOMO. And then it tanks😅🙈 5th in 5 years or so. Blegh. Never learn. Anyways, hope it shoots up to 15-20 in september due to some crazy announcement. If so, I’ll stop whining. Nice weekend and glta.
2 · Reply